Literature DB >> 19593410

Does splenectomy protect against immune-mediated complications in blunt trauma patients?

Marie Crandall1, Michael B Shapiro, Michael A West.   

Abstract

Activation of the innate immune system results from severe trauma and the resultant systemic inflammatory response is thought to mediate remote organ injury. In animal models, vagal-mediated innate immune responses have been shown to modulate proinflammatory cytokine release in response to trauma or sepsis. In those models, vagal nerve transaction and splenectomy decreased cytokine release and protected against lung injury and mortality. We hypothesized that, if similar mechanisms are active in humans, patients who require splenectomy for trauma would have better outcomes than injured patients without splenectomy. We performed a retrospective cohort study on 46,858 patients who sustained blunt liver or spleen injury utilizing the 2002 National Trauma Data Bank (NTDB). Blunt trauma patients who underwent splenectomy were compared with all patients with splenic injuries. Demographic parameters and the following outcome variables were compared: mortality, hospital length of stay (LOS), ICU length of stay (ILOS), mean ventilator days (VENT), and incidence of acute respiratory distress syndrome (ARDS). Groups were compared controlling for age, gender, injury severity score (ISS), emergency department (ED) blood pressure, and ED base deficit (BD) using multiple regression analyses. Patients that underwent splenectomy had significantly shorter LOS than patients who were managed nonoperatively or with splenorrhaphy: LOS,15.1 versus 19.3 d, P = 0.002; ILOS, 7.8 versus 10.6 d, P < 0.001; and VENT, 7.1 versus 11.4 d, P < 0.001. Adjusted mortality rates (OR 1.02; 95% CI 0.98-1.05; P = 0.29) and the reported incidence of ARDS were not significantly different between the two groups (2.4% versus 3.6%; P = 0.213). Patients who underwent splenectomy demonstrated better secondary outcomes than patients who were managed nonoperatively or with splenorrhaphy, even when controlling for injury severity and physiologic derangements. It is possible that the improved outcomes seen in the group undergoing splenectomy were due to favorable modulation of the human innate immune inflammatory response after trauma.

Entities:  

Mesh:

Year:  2009        PMID: 19593410      PMCID: PMC2707521          DOI: 10.2119/molmed.2009.00029

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  27 in total

1.  Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia.

Authors:  Valentin A Pavlov; Mahendar Ochani; Margot Gallowitsch-Puerta; Kanta Ochani; Jared M Huston; Christopher J Czura; Yousef Al-Abed; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

2.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.

Authors:  J P Mira; A Cariou; F Grall; C Delclaux; M R Losser; F Heshmati; C Cheval; M Monchi; J L Teboul; F Riché; G Leleu; L Arbibe; A Mignon; M Delpech; J F Dhainaut
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

Review 3.  Splenic function: normal, too much and too little.

Authors:  E R Eichner
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

Review 4.  Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle?

Authors:  A E Baue; R Durham; E Faist
Journal:  Shock       Date:  1998-08       Impact factor: 3.454

5.  Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank.

Authors:  M Margaret Knudson; Danagra G Ikossi; Linda Khaw; Diane Morabito; Larisa S Speetzen
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

Review 6.  Nonoperative management of blunt hepatic trauma is the treatment of choice for hemodynamically stable patients. Results of a prospective trial.

Authors:  M A Croce; T C Fabian; P G Menke; L Waddle-Smith; G Minard; K A Kudsk; J H Patton; M J Schurr; F E Pritchard
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

7.  Evolution of management of major hepatic trauma: identification of patterns of injury.

Authors:  D C Boone; M Federle; T R Billiar; A O Udekwu; A B Peitzman
Journal:  J Trauma       Date:  1995-08

8.  Nonoperative management of blunt splenic trauma: a multicenter experience.

Authors:  T H Cogbill; E E Moore; G J Jurkovich; J A Morris; P Mucha; S R Shackford; R T Stolee; F A Moore; S Pilcher; R LoCicero
Journal:  J Trauma       Date:  1989-10

9.  Preexisting conditions and mortality in older trauma patients.

Authors:  Gerald McGwin; Paul A MacLennan; Jessaka Bailey Fife; Gregory G Davis; Loring W Rue
Journal:  J Trauma       Date:  2004-06

10.  Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis.

Authors:  Jared M Huston; Mahendar Ochani; Mauricio Rosas-Ballina; Hong Liao; Kanta Ochani; Valentin A Pavlov; Margot Gallowitsch-Puerta; Mala Ashok; Christopher J Czura; Brian Foxwell; Kevin J Tracey; Luis Ulloa
Journal:  J Exp Med       Date:  2006-06-19       Impact factor: 14.307

View more
  10 in total

Review 1.  Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery?

Authors:  Nikunj Satani; Sean I Savitz
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

2.  JAK2 inhibition prevents innate immune responses and rescues animals from sepsis.

Authors:  Geber Peña; Bolin Cai; Edwin A Deitch; Luis Ulloa
Journal:  J Mol Med (Berl)       Date:  2010-08       Impact factor: 4.599

3.  Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis.

Authors:  Geber Peña; Bolin Cai; Jun Liu; Esmerij P van der Zanden; Edwin A Deitch; Wouter J de Jonge; Luis Ulloa
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

4.  β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system.

Authors:  Gergely Vida; Geber Peña; Alexandre Kanashiro; Maria del Rocio Thompson-Bonilla; David Palange; Edwin A Deitch; Luis Ulloa
Journal:  FASEB J       Date:  2011-08-12       Impact factor: 5.191

Review 5.  Influence of the National Trauma Data Bank on the study of trauma outcomes: is it time to set research best practices to further enhance its impact?

Authors:  Adil H Haider; Taimur Saleem; Jeffrey J Leow; Cassandra V Villegas; Mehreen Kisat; Eric B Schneider; Elliott R Haut; Kent A Stevens; Edward E Cornwell; Ellen J MacKenzie; David T Efron
Journal:  J Am Coll Surg       Date:  2012-02-07       Impact factor: 6.113

Review 6.  The spleen in local and systemic regulation of immunity.

Authors:  Vincenzo Bronte; Mikael J Pittet
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

7.  What's new in critical illness and injury science? State of the art in management of ARDS.

Authors:  Stanislaw P Stawicki; Mamta Swaroop; Sagar C Galwankar; Thomas J Papadimos
Journal:  Int J Crit Illn Inj Sci       Date:  2014-04

8.  Splenectomy is associated with altered leukocyte kinetics after severe trauma.

Authors:  Michel Paul Johan Teuben; Arne Hollman; Taco Blokhuis; Roman Pfeifer; Roy Spijkerman; Henrik Teuber; Hans-Christoph Pape; Luke Petrus Hendrikus Leenen
Journal:  Eur J Med Res       Date:  2021-03-15       Impact factor: 2.175

9.  IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome.

Authors:  Chuan-Jiang Wang; Mu Zhang; Hua Wu; Shi-Hui Lin; Fang Xu
Journal:  Int Immunopharmacol       Date:  2018-12-22       Impact factor: 4.932

10.  Splenectomy modulates early immuno-inflammatory responses to trauma-hemorrhage and protects mice against secondary sepsis.

Authors:  S Drechsler; J Zipperle; P Rademann; M Jafarmadar; A Klotz; S Bahrami; M F Osuchowski
Journal:  Sci Rep       Date:  2018-10-05       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.